Tomorrow, Kezar’s CEO, Chris Kirk, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: https://lnkd.in/eQbXMpBN #HCWainwrightGlobal
Kezar Life Sciences
Biotechnology Research
South San Francisco, California 5,061 followers
Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders
About us
We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.
- Website
-
https://kezarlifesciences.com/
External link for Kezar Life Sciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- Biotechnology, Autoimmune Disease, Immunology, Oncology, Drug Discovery, and Drug Development
Locations
-
Primary
Get directions
4000 Shoreline Ct
Suite 300
South San Francisco, California 94080, US
Employees at Kezar Life Sciences
Updates
-
Kezar Life Sciences reposted this
Targeted treatments that are potentially steroid-sparing are on the horizon for #lupusnephritis. Read about it in @FrontIn [https://lnkd.in/d5PDRnze]. #openaccess @kezarbio
-
Today, we announced our participation at the H.C. Wainwright 26th Annual Global Investment Conference in #NewYorkCity next week. Learn more about our upcoming presentation in our latest press release here: https://lnkd.in/gyVPictb #HCWainwrightGlobal
-
-
Kezar Life Sciences reposted this
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
-
-
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
-
-
We are excited to share that our partner, Everest Medicines, has dosed the first patient in China. Their team continues to integrate seamlessly with ours to drive forward our global Phase 2b clinical trial evaluating zetomipzomib in adults living with LN. https://lnkd.in/gJu83GfZ
-
Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at https://lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib #LupusNephritis
-
-
Kezar Life Sciences reposted this
Section Chief of Hepatology/Associate Director of Organ Transplantation at Rush University Medical Center
Let’s aim for a steroid-free future to treat #autoimmunehepatitis! Read about treatments in development for #AIH in @HepCommJournal [https://lnkd.in/gGd4QDFX]. #openacess https://lnkd.in/gjnJ8wEy